ADVA
30.4.2020 09:02:05 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso has deployed its ConnectGuard™ Cloud encryption solution for robust software-based network protection. By leveraging the industry-first cloud-native technology, the IT service provider is ensuring end-to-end security for its virtual private network (VPN). The cost-effective and low-latency solution is now safeguarding connectivity between dacoso’s data centers in Germany, Austria and Switzerland, as well as its virtual cloud services. The deployment improves dacoso’s bandwidth efficiency while complying with all relevant industry standards. Also, by moving to a cloud-native security solution, dacoso’s mission-critical network benefits from enhanced flexibility and cost-efficiency.
“By deploying ADVA’s ConnectGuard™ Cloud technology, we’re harnessing virtualized encryption that’s flexible, scalable and doesn’t come with a heavy bandwidth penalty. The solution ensures rigorous data protection for both our branches and our cloud locations. And, because it works without large additional data ballast, it also improves network utilization and reduces cost-per-encrypted-bit,” said Karsten Geise, head of business and product development, dacoso. “Now our cloud network meets all regulatory requirements, such as GDPR, while being simpler and more efficient. Removing the need for hardware appliances also frees up valuable rack space and means we can easily shop around for new innovation in the future rather than being constrained by single-vendor lock-in.”
dacoso provides managed services for businesses that rely on the highest levels of security, including virtual environments. As hardware-based encryption isn’t possible in cloud provider data centers, the software-based protection that ConnectGuard™ Cloud offers is vital. Based on ADVA’s industry-leading Ensemble Connector virtualization platform, the solution delivers a host of benefits. These include end-to-end encryption at Layer 2, 3 and 4, along with improved latency and throughput performance compared to IPSec. With its zero-touch provisioning and automated key management, ADVA’s unique cloud-native technology also significantly simplifies operations for dacoso’s team. Complexity is further reduced by automated key distribution and management, centrally orchestrated by the ADVA Ensemble Controller management solution.
“dacoso now has all the advantages of highly efficient and extremely rigorous encryption, delivered entirely through software. That means ultra-low latency protection at Layers 2, 3 and 4, as well as unrivaled advantages in terms of scale and ease of use,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “ConnectGuard™ Cloud really is the ultimate solution for site-to-site and site-to-cloud encrypted VPNs. It’s also the perfect fit for dacoso’s needs. With transport-layer independent security, they can rely on comprehensive protection that won’t affect the performance of the services it provides. What’s more, as part of our Ensemble portfolio of open NFV solutions, ConnectGuard™ Cloud unshackles dacoso from vendor lock-in and offers freedom to mix and match new technologies in the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Cyber Security and Virtual Networking. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso services comprise, among other, optical data links encrypted to satisfy BSI, a certified Security Operation Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen, Frankfurt a.M., with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
